Since MHC II is known to interact with lymphocyte activation gene 3 (LAG3) [54], an immune checkpoint inhibitor which is also present on primary NK‐cells [55], we sought to examine the direct impact of MHC II and LAG‐3 interaction in melanoma resistance to NKmK. The gene discussed is LAG3; the disease is melanoma.